Marketing Authorisation for Xonvea in Ireland

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that Xonvea^® has gained marketing approval in the Republic of Ireland from the country's medicines regulator, the Health Products Regulatory Authority, for the treatment of nausea and vomiting of pregnancy where conservative management has failed.

Approval in Ireland paves the way for Alliance's first launch of Xonvea outside the UK, where the product was in-licensed from Duchesnay Inc. of Canada in 2015 and launched in October 2018. In Ireland it has been approved for the same indication, nausea and vomiting of pregnancy where conservative management has failed.

In Ireland, as in the UK, nausea and vomiting of pregnancy ("NVP") is the most common medical condition in pregnancy, affecting approximately 46,500 women in Ireland each year* (70%-80% of pregnant women). Research shows that up to 40% of pregnant women report symptoms of nausea and vomiting sufficiently severe to interfere with daily life with at least 1 in 100-150 women hospitalised with the condition in Ireland each year.

It is expected that Xonvea will be launched in Ireland in Q4 2019 and will be marketed directly by Alliance's in-country sales and marketing team.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.